For the third quarter of 2026, analysts anticipate Upstream Bio will report a loss of $0.73 per share on revenue of approximately $0.52 million, with its current stock price of $3.26 trading significantly below the average analyst price target of $29.83.
The primary narrative for this report is the initiation of pivotal Phase 3 trials for verekitug, the company’s lead TSLP receptor antagonist for severe asthma and CRSwNP.
Following a volatile period after earlier Phase 2 data readouts, management has committed to a quarterly dosing regimen to differentiate the asset from existing market biologics.
Investors are specifically monitoring the ramp-up in research and development expenses as the company prepares for these large-scale studies while managing a cash runway projected to last through 2027.